세계의 유전자 침묵 시장 : 장래 예측 - 제품 및 서비스별, 메커니즘별, 기술별, 용도별, 최종 사용자별, 지역별 분석(-2032년)

According to Stratistics MRC, the Global Gene Silencing Market is accounted for $11.48 billion in 2025 and is expected to reach $32.07 billion by 2032 growing at a CAGR of 15.8% during the forecast period. Gene silencing is a natural biological process that regulates gene expression by preventing specific genes from producing proteins or other gene products. It can occur at the transcriptional or post-transcriptional level, effectively "turning off" a gene without altering its DNA sequence. Mechanisms such as RNA interference (RNAi), DNA methylation, and histone modification play key roles in this process. Gene silencing helps control cellular functions, maintain genome stability, and defend against viruses or transposable elements. It is also widely used in biotechnology and medicine for studying gene function and developing treatments for genetic and infectious diseases.

Market Dynamics:

Driver:

Rising prevalence of genetic & chronic diseases

RNA interference (RNAi), antisense oligonucleotides (ASOs), and CRISPR-based silencing platforms enable targeted modulation of disease-causing genes. Pharmaceutical firms and biotech startups are scaling silencing pipelines to address conditions such as Huntington's, ALS, and hereditary cancers. Integration with genomic profiling and delivery systems enhances therapeutic precision and tissue targeting. Demand for non-invasive and durable interventions is rising across personalized medicine and orphan drug programs. These dynamics are propelling platform innovation and clinical adoption across gene silencing ecosystems.

Restraint:

Safety and immunogenicity concerns

Off-target effects, immune activation, and toxicity risks degrade platform reliability and patient outcomes. Delivery vehicles such as viral vectors and lipid nanoparticles must balance efficacy with biocompatibility and clearance. Regulatory bodies require extensive preclinical validation and long-term safety data to approve silencing candidates. Clinical trial delays and adverse event reporting continue to hinder investor confidence and pipeline progression. These constraints are hampering adoption across high-risk and immunologically sensitive therapeutic areas.

Opportunity:

Successful clinical proof-of-concept and approvals

FDA and EMA approvals of RNAi-based drugs such as patisiran and givosiran validate therapeutic efficacy and commercial viability. Clinical trials demonstrate durable gene knockdown, symptom reduction, and biomarker improvement across rare and chronic conditions. Expansion into oncology, metabolic, and infectious disease indications is accelerating across academic and industry sponsors. Demand for scalable and regulatory-aligned silencing platforms is rising across pharma partnerships and licensing deals. These trends are fostering growth across clinical translation and therapeutic diversification.

Threat:

Intellectual property & market competition

Patent disputes, licensing restrictions, and freedom-to-operate challenges constrain innovation and market entry. Dominance of early movers and proprietary delivery systems limits access for emerging players and academic spinouts. Fragmented IP landscapes complicate cross-border commercialization and strategic alliances. Competitive pressure from CRISPR, base editing, and epigenetic modulation platforms reduces investor focus on traditional silencing modalities. These risks continue to limit platform scalability and long-term positioning across therapeutic markets.

Covid-19 Impact:

The pandemic disrupted clinical trials, manufacturing, and regulatory timelines across gene silencing programs. Lockdowns and resource reallocation delayed patient recruitment and data collection across rare disease and oncology trials. However, interest in RNA-based platforms surged due to mRNA vaccine success and public awareness of genetic medicine. Investment in delivery systems, immunogenicity mitigation, and remote monitoring accelerated platform innovation. Post-pandemic strategies now include gene silencing as a core pillar of precision medicine and therapeutic resilience. These shifts are reinforcing long-term investment and regulatory engagement across silencing technologies.

The RNA interference (RNAi) segment is expected to be the largest during the forecast period

The RNA interference (RNAi) segment is expected to account for the largest market share during the forecast period due to its validated mechanism, clinical maturity, and broad applicability across disease areas. RNAi platforms use siRNA and shRNA constructs to silence target genes with high specificity and durability. Integration with lipid nanoparticle delivery and tissue-specific promoters enhances therapeutic precision and safety. Approved RNAi drugs and late-stage candidates demonstrate efficacy across liver, nerve, and ocular indications. Demand for scalable and modular RNAi platforms is rising across pharma pipelines and academic research.

The software & bioinformatics tools segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the software & bioinformatics tools segment is predicted to witness the highest growth rate as data complexity and target validation drive demand for advanced analytics. Platforms support sequence design, off-target prediction, and delivery optimization across RNAi, ASO, and CRISPR workflows. AI and machine learning algorithms enable biomarker discovery, toxicity modelling, and patient stratification across clinical cohorts. Cloud-based infrastructure and modular pipelines improve scalability and accessibility across research and commercial environments. Demand for interoperable, secure, and clinically validated bioinformatics tools is rising across silencing development and regulatory submission.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to its advanced biotech ecosystem, regulatory clarity, and clinical infrastructure. U.S. and Canadian firms deploy gene silencing platforms across rare disease, oncology, and neurology programs with integrated delivery and analytics. Investment in genomic medicine, academic-industry partnerships, and FDA engagement supports platform scalability and validation. Presence of leading therapeutic developers, CROs, and research institutions drives innovation and standardization. These factors are propelling North America's leadership in gene silencing commercialization and clinical translation.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR as healthcare modernization, genetic disease burden, and biotech investment converge across regional economies. Countries like China, India, Japan, and South Korea scale gene silencing platforms across public health programs, academic research, and clinical trials. Government-backed initiatives support infrastructure development, startup incubation, and international collaboration across RNA and oligonucleotide therapeutics. Local firms offer cost-effective and regionally adapted solutions tailored to disease profiles and compliance needs. These trends are accelerating regional growth across gene silencing innovation and therapeutic deployment.

Key players in the market

Some of the key players in Gene Silencing Market include Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, Silence Therapeutics, Dicerna Pharmaceuticals, Sirnaomics, Arbutus Biopharma, Olix Pharmaceuticals, Benitec Biopharma, Sylentis, Genevant Sciences, RXi Pharmaceuticals, Intellia Therapeutics, Editas Medicine and Beam Therapeutics.

Key Developments:

In September 2025, Ionis secured FDA approvals for TRYNGOLZA (for familial chylomicronemia syndrome, FCS) and DAWNZERA (for hereditary angioedema, HAE), marking a pivotal commercial milestone. Clinical trials showed 72% triglyceride reduction and 85% fewer pancreatitis events for olezarsen, the active compound in TRYNGOLZA. These approvals validate Ionis' RNA-targeted platform and expand its rare disease portfolio.

In February 2025, Alnylam unveiled its TRITON Phase 3 program for nucresiran, a next-generation TTR silencer targeting ATTR-CM and hATTR-PN. The candidate builds on Alnylam's RNAi leadership in amyloidosis and aims to deliver durable knockdown with improved delivery. It complements the company's existing portfolio and supports long-term franchise sustainability in rare diseases.

Product & Services Covered:

• Reagents & Kits
• Instruments
• Oligonucleotides & RNA Molecules
• Software & Bioinformatics Tools
• Gene Silencing Services
• Other Product & Services

Mechanisms Covered:

• Transcriptional Gene Silencing
• Post-Transcriptional Gene Silencing
• Epigenetic Modulation

Technologies Covered:

• RNA Interference (RNAi)
• Antisense Oligonucleotides (ASOs)
• CRISPR Interference (CRISPRi)
• Epigenetic Silencing
• siRNA/shRNA Delivery Systems

Applications Covered:

• Drug Discovery & Development
• Therapeutics Manufacturing
• Functional Genomics
• Target Validation
• Disease Modeling
• Other Applications

End Users Covered:

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutions
• CROs & CDMOs
• Hospitals & Diagnostic Labs
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Technology Analysis
• 3.8 Application Analysis
• 3.9 End User Analysis
• 3.10 Emerging Markets
• 3.11 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Gene Silencing Market, By Product & Service

• 5.1 Introduction
• 5.2 Reagents & Kits
• 5.3 Instruments
• 5.4 Oligonucleotides & RNA Molecules
• 5.5 Software & Bioinformatics Tools
• 5.6 Gene Silencing Services
• 5.7 Other Product & Services

6 Global Gene Silencing Market, By Mechanism

• 6.1 Introduction
• 6.2 Transcriptional Gene Silencing
• 6.3 Post-Transcriptional Gene Silencing
• 6.4 Epigenetic Modulation

7 Global Gene Silencing Market, By Technology

• 7.1 Introduction
• 7.2 RNA Interference (RNAi)
• 7.3 Antisense Oligonucleotides (ASOs)
• 7.4 CRISPR Interference (CRISPRi)
• 7.5 Epigenetic Silencing
• 7.6 siRNA/shRNA Delivery Systems

8 Global Gene Silencing Market, By Application

• 8.1 Introduction
• 8.2 Drug Discovery & Development
• 8.3 Therapeutics Manufacturing
• 8.4 Functional Genomics
• 8.5 Target Validation
• 8.6 Disease Modeling
• 8.7 Other Applications

9 Global Gene Silencing Market, By End User

• 9.1 Introduction
• 9.2 Pharmaceutical & Biotechnology Companies
• 9.3 Academic & Research Institutions
• 9.4 CROs & CDMOs
• 9.5 Hospitals & Diagnostic Labs
• 9.6 Other End Users

10 Global Gene Silencing Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 Alnylam Pharmaceuticals
• 12.2 Ionis Pharmaceuticals
• 12.3 Arrowhead Pharmaceuticals
• 12.4 Silence Therapeutics
• 12.5 Dicerna Pharmaceuticals
• 12.6 Sirnaomics
• 12.7 Arbutus Biopharma
• 12.8 Olix Pharmaceuticals
• 12.9 Benitec Biopharma
• 12.10 Sylentis
• 12.11 Genevant Sciences
• 12.12 RXi Pharmaceuticals
• 12.13 Intellia Therapeutics
• 12.14 Editas Medicine
• 12.15 Beam Therapeutics